Abstract
The aim of the study was to examine the value of the combination of an elevated C-reactive protein and hypoalbuminaemia (GPS) in predicting cancer-specific survival after resection for colon and rectal cancer. The GPS was constructed as follows: Patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. A GPS of 1 (n = 109) was mainly due to an elevated C-reactive protein concentration and the remainder due to hypoalbuminaemia. In those patients with a GPS of 1 due to hypoalbuminaemia (n = 16), the 3-year overall survival rate was 94% compared with 62% in those patients with a GPS of 1 due to an elevated C-reactive protein concentration (n = 93, p = 0.0094). Therefore, the GPS was modified such that patients with hypoalbuminaemia were assigned a score of 0 in the absence of an elevated C-reactive protein. On univariate analysis of those patients with colon and rectal cancer, the modified GPS (p < 0.0001) was significantly associated with overall and cancer specific survival. On univariate survival analysis of those patients with Dukes B colon and rectal cancer, the modified GPS (p < 0.01) was significantly associated with overall and cancer specific survival. The results of the present study indicate that the GPS, before surgery, predicts overall and cancer-specific survival after resection of colon and rectal cancer.
MeSH Terms
Aged
Biomarkers/blood
C-Reactive Protein/analysis
Colonic Neoplasms/blood,mortality,surgery
Digestive System Surgical Procedures
Disease-Free Survival
Female
Health Status Indicators
Humans
Hypoalbuminemia/blood
Inflammation/blood
Male
Middle Aged
Predictive Value of Tests
Rectal Neoplasms/blood,mortality,surgery
Reproducibility of Results
Serum Albumin/analysis
Treatment Outcome
Chemicals
Biomarkers
Serum Albumin
C-Reactive Protein
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Crozier Joseph E M
Canna Khalid
Angerson Wilson J
McArdle Colin S
References (21)
21 references, click to expand
-
Inflammatory markers and cardiovascular health in older adults.
Cardiovasc Res. 2005 May 1;66(2):265-75
PMID: 15820195
-
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Ann Oncol. 2003 Jul;14(7):1026-38
PMID: 12853343
-
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.
Br J Cancer. 2006 Jan 30;94(2):227-30
PMID: 16404432
-
Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.
Pancreatology. 2006;6(5):450-3
PMID: 16847382
-
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.
Ann Surg Oncol. 2000 Sep;7(8):617-23
PMID: 11005561
-
Risk factors for morbidity and mortality after colectomy for colon cancer.
Dis Colon Rectum. 2000 Jan;43(1):83-91
PMID: 10813129
-
Systemic inflammatory response predicts survival following curative resection of colorectal cancer.
Br J Surg. 2003 Feb;90(2):215-9
PMID: 12555298
-
Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program.
Ann Surg. 1998 Jul;228(1):64-70
PMID: 9671068
-
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31
PMID: 16631506
-
Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.
Br J Cancer. 2006 Mar 13;94(5):637-41
PMID: 16479253
-
Serum albumin: a prognostic indicator in patients with colorectal cancer.
J R Coll Surg Edinb. 1998 Jun;43(3):163-8
PMID: 9654876
-
Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss.
Nutr Cancer. 2001;39(2):210-3
PMID: 11759282
-
Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation.
Br J Cancer. 2002 Feb 1;86(3):331-5
PMID: 11875693
-
Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients.
Nutr Cancer. 1998;31(2):101-5
PMID: 9770720
-
A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.
Br J Cancer. 2005 May 23;92(10):1834-6
PMID: 15870712
-
Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.
World J Surg. 1999 Jun;23(6):584-8
PMID: 10227928
-
Cachexia.
Ann Intern Med. 2000 Oct 17;133(8):622-34
PMID: 11033592
-
Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer.
Am J Surg. 1998 Oct;176(4):335-8
PMID: 9817250
-
Cachexia: pathophysiology and clinical relevance.
Am J Clin Nutr. 2006 Apr;83(4):735-43
PMID: 16600922
-
The spread of rectal cancer and its effect on prognosis.
Br J Cancer. 1958 Sep;12(3):309-20
PMID: 13596482
-
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.
Br J Cancer. 2003 Sep 15;89(6):1028-30
PMID: 12966420